Overview: 17-Hydroxy-Pregnenolone TestIntroduction: The 17-Hydroxy-Pregnenolone Test measures 17-hydroxypregnenolone, a steroid hormone produced by the adrenal glands, to diagnose disorders such as congenital adrenal hyperplasia (CAH) or adrenal tumors, which can cause fatigue, weight changes, or blood pressure issues. Aligned with 2023 Endocrine Society guidelines, this test employs an immunoassay method for high sensitivity and accuracy, aiding in the confirmation of adrenal dysfunction. It is critical for initiating treatments like hormone replacement or surgical interventions, preventing complications such as adrenal crisis, and improving patient outcomes in endocrinology.
Other Names: 17-OH Pregnenolone Assay, 17-Hydroxypregnenolone Test.
FDA Status: Laboratory-developed test (LDT), adhering to endocrinology standards for diagnostic reliability.
Historical Milestone: Identified in the 1950s as a key adrenal steroid, 17-hydroxypregnenolone measurement advanced with immunoassays in the 1980s. By the 2000s, standardized automated assays enhanced its clinical utility for adrenal disorder diagnostics.
Purpose: Diagnoses adrenal gland disorders, guides hormone therapy, and monitors disease progression in patients with symptoms like fatigue or abnormal blood pressure.
Test Parameters: 1. 17-Hydroxypregnenolone
Pretest Condition: Fasting for 10-12 hours is required. Collect serum or plasma in the morning due to diurnal hormone variation. Report symptoms like fatigue, weight changes, or medications (e.g., steroids) that may affect results. Avoid biotin supplements, which can interfere with the assay.
Specimen: 2-5 mL serum (serum separator tube, SST) or 2-4 mL plasma (EDTA tube). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours, protected from light to maintain hormone stability.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document symptoms such as fatigue, weight changes, high or low blood pressure, or a family history of adrenal or endocrine disorders. Include current medications, particularly steroids or hormonal treatments.
Consent: Written consent is required, detailing the test's purpose, diagnostic implications, and potential need for hormone therapy or surgical intervention.
Procedural Considerations: Utilizes an immunoassay (ELISA or radioimmunoassay) to measure 17-hydroxypregnenolone levels. Results are typically available in 1-2 days, enabling rapid clinical decisions. The test is performed in laboratories with rigorous quality controls.
Factors Affecting Result Accuracy: Steroids or biotin supplements may cause false results. Hemolysis, lipemia, or improper sample storage can degrade specimen quality. Morning collection is essential due to diurnal hormone fluctuations.
Clinical Significance: Elevated 17-hydroxypregnenolone levels suggest CAH or adrenal tumors, prompting further testing or treatment. Normal levels may necessitate additional tests, such as ACTH stimulation or adrenal imaging, to rule out subtle adrenal dysfunction.
Specialist Consultation: Consult an endocrinologist for result interpretation and management. Genetic counseling is recommended if CAH or familial adrenal disorders are suspected.
Additional Supporting Tests: ACTH, cortisol, or adrenal imaging (CT/MRI) to confirm adrenal dysfunction or evaluate gland morphology.
Test Limitations: False results may occur due to interfering medications or improper sample timing. Mild adrenal dysfunction may require stimulation testing for detection.
References: Endocrine Society CAH Guidelines, 2023; Speiser PW, Journal of Clinical Endocrinology & Metabolism, 2022.
